Baotou Dongbao Bio-TechLtd (300239) Stock Overview
Engages in the research and development, production, and sale of gelatin, collagen, and additional products in the People’s Republic of China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Risk Analysis
No risks detected for 300239 from our risk checks.
300239 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Baotou Dongbao Bio-Tech Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥5.82 |
| 52 Week High | CN¥6.40 |
| 52 Week Low | CN¥4.43 |
| Beta | 0.098 |
| 1 Month Change | 4.49% |
| 3 Month Change | -3.96% |
| 1 Year Change | 4.49% |
| 3 Year Change | -26.14% |
| 5 Year Change | -1.86% |
| Change since IPO | 12.51% |
Recent News & Updates
Recent updates
Market Might Still Lack Some Conviction On Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239) Even After 37% Share Price Boost
Oct 08
We Like These Underlying Return On Capital Trends At Baotou Dongbao Bio-TechLtd (SZSE:300239)
Oct 01Baotou Dongbao Bio-TechLtd's (SZSE:300239) Dividend Will Be Reduced To CN¥0.022
May 27Sentiment Still Eluding Baotou Dongbao Bio-Tech Co.,Ltd (SZSE:300239)
Feb 28Shareholder Returns
| 300239 | CN Chemicals | CN Market | |
|---|---|---|---|
| 7D | -1.5% | -0.9% | -1.6% |
| 1Y | 4.5% | 29.3% | 19.9% |
Return vs Industry: 300239 underperformed the CN Chemicals industry which returned 29.3% over the past year.
Return vs Market: 300239 underperformed the CN Market which returned 19.9% over the past year.
Price Volatility
| 300239 volatility | |
|---|---|
| 300239 Average Weekly Movement | 3.1% |
| Chemicals Industry Average Movement | 5.5% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in CN Market | 9.3% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 300239 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300239's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | 1,385 | Fang Liu | www.dongbaoshengwu.com |
Baotou Dongbao Bio-Tech Co.,Ltd engages in the research and development, production, and sale of gelatin, collagen, and additional products in the People’s Republic of China and internationally. It offers gelatin for jelly, confection, yogurt, plasma substitute, tablets, softgel, photographic paper, and hard capsules; plasma gelatin substitute, hollow capsule, double protein dietary fiber, cosmetics, and other products; agglomerated collagen peptide; hydrolyzed collagen power and granule; collagen peptide power and granule; hydrolyzed fish collagen; collagen jars; and fish collagen peptide powder, as well as food additive and pharmaceutical gelatin. The company also engages in research and development, production, and sale of bio-organic fertilizers, including industrial and feed grade calcium hydrogen phosphate; inorganic and organic microorganisms fertilizers; nitrogen fertilizers; calcium amino acid fertilizer; bone-derived biological calcium fertilizer; and biological and refined organic fertilizer.
Baotou Dongbao Bio-Tech Co.,Ltd Fundamentals Summary
| 300239 fundamental statistics | |
|---|---|
| Market cap | CN¥3.39b |
| Earnings (TTM) | CN¥68.16m |
| Revenue (TTM) | CN¥784.62m |
Is 300239 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300239 income statement (TTM) | |
|---|---|
| Revenue | CN¥784.62m |
| Cost of Revenue | CN¥600.13m |
| Gross Profit | CN¥184.49m |
| Other Expenses | CN¥116.33m |
| Earnings | CN¥68.16m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.12 |
| Gross Margin | 23.51% |
| Net Profit Margin | 8.69% |
| Debt/Equity Ratio | 29.0% |
How did 300239 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/19 01:07 |
| End of Day Share Price | 2025/11/19 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Baotou Dongbao Bio-Tech Co.,Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jie Yao | Everbright Securities Co. Ltd. |